R&D | December 31, 2025
Sinopia Biosciences scores NIH grant to supercharge AI-driven drug discovery
The funding will accelerate Sinopia’s data-driven drug discovery efforts
The funding will accelerate Sinopia’s data-driven drug discovery efforts
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
The proceeds from the QIP will be used primarily to accelerate the nationwide expansion of the COCO stores of Davaindia nationwide
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
Adverse events were consistent with valbenazine’s established safety profile
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
Subscribe To Our Newsletter & Stay Updated
